---
title: "Curis to Report Fourth Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on March 19, 2026"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/278942056.md"
description: "In Lexington, Massachusetts on March 12, 2026, Curis, Inc. disclosed plans to disclose its financial results for the final quarter of 2025. The biotech firm, trading as CRIS on NASDAQ, specializes in advancing emavusertib (CA-4948), a medication that acts as an IRAK4 and FLT3 inhibitor. This orally administered, small molecule has garnered considerable attention for its potential therapeutic benefits."
datetime: "2026-03-12T20:31:43.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/278942056.md)
  - [en](https://longbridge.com/en/news/278942056.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/278942056.md)
---

# Curis to Report Fourth Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on March 19, 2026

In Lexington, Massachusetts on March 12, 2026, Curis, Inc. disclosed plans to disclose its financial results for the final quarter of 2025. The biotech firm, trading as CRIS on NASDAQ, specializes in advancing emavusertib (CA-4948), a medication that acts as an IRAK4 and FLT3 inhibitor. This orally administered, small molecule has garnered considerable attention for its potential therapeutic benefits.

### Related Stocks

- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [CRIS.US](https://longbridge.com/en/quote/CRIS.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)

## Related News & Research

- [BUZZ-Precision BioSciences up as hepatitis B gene‑editing trial expands in Europe](https://longbridge.com/en/news/282832865.md)
- [Pancreatic cancer pill shown to nearly double overall survival time, drug company says](https://longbridge.com/en/news/282687539.md)
- [Arcutis Biotherapeutics Targets ZORYVE Expansion, Raises 2026 Outlook and Turns Cash-Flow Positive](https://longbridge.com/en/news/282775123.md)
- [BUZZ-Street View: Analysts upbeat on Revolution pancreatic cancer drug](https://longbridge.com/en/news/282702171.md)
- [Revolution Medicines' experimental cancer pill helps improve survival in late-stage study](https://longbridge.com/en/news/282540793.md)